Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01932385

Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma

Sponsor: Qingdao Central Hospital

Interventions Best Supportive Care Sorafenib

Updated 7 times since 2017 Last updated: Feb 13, 2018 Started: Aug 1, 2013 Primary completion: Jan 30, 2016 Completion: Jul 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Liver Cancer, this trial is completed. The trial is conducted by Qingdao Central Hospital and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Mar 2018 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Oct 2017 — Mar 2018 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qingdao Central Hospital

Data source: Qingdao Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China